Phase III RCT in 392 patients with HR+/HER2-, PIK3CA wild-type advanced breast cancer after CDK4/6 inhibitor: median PFS 9.3 mo with gedatolisib triplet (HR 0.24) and 7.4 mo with doublet (HR 0.33) vs 2.0 mo with fulvestrant. Grade ≥3 neutropenia 62.3% with triplet.
RCTn = 392
Hurvitz et al. VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer